What did @kayysbvby actually say?
Honestly? Not much that's fact-checkable. The transcript is song lyrics, not a medical monologue. The real message lives in the caption: "I said this my last year being fat" paired with the Wegovy hashtag. That's the claim, and it's an implied one: that Wegovy is what's behind this transformation.
This is a pattern worth paying attention to on TikTok. The actual "claim" is aesthetic and aspirational, not verbal. No dosage mentioned, no mechanism explained, no promise of a specific outcome. But 486,000 views on a post implying Wegovy ends obesity deserves at least a grounded look at what the drug actually does, and what it doesn't.
Does the science back this up?
Semaglutide (Wegovy's active ingredient) has genuinely strong clinical backing for weight loss. This isn't hype. But the real-world results are more complicated than a caption suggests.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that adults with obesity using 2.4mg semaglutide weekly lost an average of 14.9% of body weight over 68 weeks versus 2.4% with placebo. That's a meaningful difference. The SELECT trial (Lincoff et al., 2023, NEJM) added cardiovascular outcome data, showing a 20% reduction in major adverse cardiac events in people with obesity and established cardiovascular disease.
So yes, Wegovy works. But "my last year being fat" sets an expectation that weight loss is linear, permanent, and complete. The STEP 1 data also showed that most participants regained two-thirds of lost weight within a year of stopping the drug (Wilding et al., 2022, Diabetes, Obesity and Metabolism). The drug doesn't cure obesity. It manages it, often requiring long-term use.
What did they get wrong (or right)?
Credit where it's due: there's nothing medically wrong in this video. No dangerous dosing advice, no fake mechanism claims, no selling compounded knockoffs as equivalent to the brand name. The creator didn't say anything false because they barely said anything at all about the drug.
What's worth pushing back on is the framing. Declaring a "last year being fat" implies a finish line that the clinical literature doesn't really support. Obesity is a chronic condition with a biological basis, not a phase you complete and exit. The GLP-1 receptor agonist space has a visibility problem where success stories dominate and the dropout rates, side effect profiles, and rebound data stay quiet.
About 40-50% of patients discontinue semaglutide within the first year in real-world settings (Khera et al., 2023, JAMA Internal Medicine). Nausea, vomiting, and gastrointestinal side effects are the most common reasons. That context doesn't make the drug bad, but it matters when 486,000 people are watching an unreservedly optimistic caption.
What should you actually know?
If you're considering Wegovy because a video made it look like the obvious answer, here are the things that don't make it into captions. Wegovy is FDA-approved for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. It requires a prescription and ongoing medical supervision.
The drug works by mimicking GLP-1, a gut hormone that regulates appetite and blood sugar. It slows gastric emptying and acts on brain receptors involved in satiety. It is not a metabolism booster or a fat burner in the traditional sense. It reduces appetite. Consistently. Over time. That's the mechanism.
Cost and access remain real barriers. Wegovy's list price sits around $1,300 per month in the US without insurance coverage. Insurance coverage is inconsistent. And the rise of compounded semaglutide, which is not the same as FDA-approved Wegovy, has created a parallel market with significant quality control concerns. The FDA has flagged compounded semaglutide safety issues repeatedly since 2023.
If this video inspires you to talk to a doctor about GLP-1 options, that's a reasonable next step. If it makes you feel like you just need to find the product and start, that's where things get risky.